全文获取类型
收费全文 | 194752篇 |
免费 | 19818篇 |
国内免费 | 8409篇 |
专业分类
耳鼻咽喉 | 1492篇 |
儿科学 | 2387篇 |
妇产科学 | 2501篇 |
基础医学 | 44826篇 |
口腔科学 | 5569篇 |
临床医学 | 12566篇 |
内科学 | 27361篇 |
皮肤病学 | 3645篇 |
神经病学 | 18110篇 |
特种医学 | 4716篇 |
外国民族医学 | 49篇 |
外科学 | 15962篇 |
综合类 | 24565篇 |
一般理论 | 2篇 |
预防医学 | 6436篇 |
眼科学 | 3658篇 |
药学 | 25719篇 |
47篇 | |
中国医学 | 6733篇 |
肿瘤学 | 16635篇 |
出版年
2024年 | 144篇 |
2023年 | 2749篇 |
2022年 | 3797篇 |
2021年 | 6581篇 |
2020年 | 6877篇 |
2019年 | 6561篇 |
2018年 | 6349篇 |
2017年 | 7010篇 |
2016年 | 6972篇 |
2015年 | 7853篇 |
2014年 | 11933篇 |
2013年 | 13617篇 |
2012年 | 11489篇 |
2011年 | 13671篇 |
2010年 | 11096篇 |
2009年 | 10903篇 |
2008年 | 11101篇 |
2007年 | 10318篇 |
2006年 | 9237篇 |
2005年 | 8154篇 |
2004年 | 6903篇 |
2003年 | 5841篇 |
2002年 | 4398篇 |
2001年 | 3757篇 |
2000年 | 3113篇 |
1999年 | 2710篇 |
1998年 | 2236篇 |
1997年 | 2213篇 |
1996年 | 1971篇 |
1995年 | 2298篇 |
1994年 | 2090篇 |
1993年 | 1889篇 |
1992年 | 1550篇 |
1991年 | 1420篇 |
1990年 | 1221篇 |
1989年 | 1122篇 |
1988年 | 1009篇 |
1987年 | 970篇 |
1986年 | 991篇 |
1985年 | 1425篇 |
1984年 | 1319篇 |
1983年 | 988篇 |
1982年 | 1083篇 |
1981年 | 875篇 |
1980年 | 780篇 |
1979年 | 663篇 |
1978年 | 429篇 |
1977年 | 343篇 |
1976年 | 339篇 |
1975年 | 173篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。 相似文献
2.
3.
4.
5.
Since their inception in the 1960s–70s, mesenchymal stem/stromal cells (MSCs) have gained interest because of their differentiation potential, anti-inflammatory effects, and immune-modulating properties. Both cell-based and cell-free MSC treatments show healing capacity in injured tissues. Cell-based treatment comprises MSCs and all secreted products, whereas cell-free treatments include only the secreted products. MSCs are therapeutically administered to many damaged organs owing to their efficacy. Specifically, the eye is a unique organ system to study the effects of MSCs, as treatment is easily applied and measured owing to its external location. The eye holds an immune-privileged status, wherein inflammation and immune responses are innately down-regulated. As excessive inflammation in the cornea often leads to fibrosis and irreversible corneal hazing, many studies have investigated the anti-inflammatory and immune-modulating capacities of MSCs. Decades of research suggest that MSCs modulate the immune response by secreting cytokines, growth factors, and extracellular matrix proteins that inhibit the infiltration of inflammatory cells following injury and promote a healing phenotype via M2 macrophage polarization. MSCs have also shown trans-differentiation potential into cornea-specific cell types during the wound healing process, such as corneal epithelial, stromal, or endothelial cells. This review discusses recent investigations of MSC treatment in the cornea, focusing on therapeutic efficacy, mechanisms, and future directions. 相似文献
6.
7.
Effect of Replacement of Wharton Acellular Jelly With FBS on the Expression of Megakaryocyte Linear Markers in Hematopoietic Stem Cells CD34+ 下载免费PDF全文
zahra Jalili Behnam Emamgolizadeh Hossein Abbaszadeh Shahla JaliliMehdi Derakhshani Mehdi YousefiMehdi TalebiKarim Shams Asenjan Ali Akabr Movassaghpour 《Asian Pacific journal of cancer prevention》2022,23(10):3281-3286
Objective: Animal environments for the growth of stem cells cause the transmission of some diseases and immune problems for the recipient. Accordingly, replacing these environments with healthy environments, at least with human resources, is essential. One of the media that can be used as an alternative to animal serums is Wharton acellular jelly (AWJ). Therefore, in this study, we intend to replace FBS with Wharton jelly and investigate its effect on the expression of megakaryocyte-related genes and markers in stem cells. Materials and Methods: In this study, cord blood-derived CD34 positive HSCs were cultured and expanded in the presence of cytokines including SCF, TPO, and FLT3-L. Then, the culture of expanded CD34 positive HSCs was performed in two groups: 1) IMDM culture medium containing 10% FBS and 100 ng / ml thrombopoietin cytokine 2) IMDM culture medium containing 10% AWJ, 100 ng / ml thrombopoietin cytokine. Finally, CD41 expressing cells were analyzed with the flow cytometry method. The genes related to megakaryocyte lineage including FLI1 and GATA2 were also evaluated using the RT-PCR technique. Results: The expression of CD41, a specific marker of megakaryocyte lineage in culture medium containing Wharton acellular jelly was increased compared to the FBS group. Additionally, the expression of GATA2 and FLI1 genes was significantly increased related to the control group. Conclusion: This study provided evidence of differentiation of CD34 positive hematopoietic stem cells from umbilical cord blood to megakaryocytes in a culture medium containing AWJ. 相似文献
8.
外泌体是一类直径为30~100 nm的圆盘囊泡,其内包含许多组分,诸如复杂RNA和蛋白质等,主要参与细胞间的信号转导。肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)是肿瘤微环境中普遍存在的巨噬细胞,通过对肿瘤生长、免疫逃逸、侵袭和转移、耐药性等多方面的作用影响肿瘤进程。外泌体在肿瘤相关巨噬细胞的招募、极化及抗肿瘤免疫调控等方面发挥着重要的调节功能。同时,TAMs以外泌体为媒介作用于肿瘤细胞,从而构成了外泌体、TAMs与肿瘤细胞之间相互作用的调控通路。综上所述,本文旨在阐明肿瘤细胞与TAMs之间,以外泌体为“桥梁”相互影响的潜在机制,以及靶向肿瘤细胞和TAMs来源的外泌体在恶性肿瘤治疗中的展望。 相似文献
9.
10.